Friday 6 November 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue: +9.30%
EPS: +25.9%
Free cash flow: +20.4%
Total debt: +21.0%

Quarter to September 2026, against a year earlier

119.66 4.45 −3.59%

Follow HAE

Alert me

Market cap: $5.7B
P/E: 54.5×
Fwd P/E: 30.2×
Dividend yield: —
F-score: 6/9
Altman Z: 2.21
Beneish M: −2.81
Dividend safety: n/a

Overview

Haemonetics Corporation (HAE) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Haemonetics Corporation (HAE) trades at a price to free cash flow of 18.1×. Over the past ten years it has ranged from 0.0× (December 2015) to 3,218× (March 2016); the current reading is higher than 17% of that period. That is below the Medical Devices industry median of 28.8× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/HAE/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Haemonetics Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/HAE/metrics/price-to-free-cash-flow">Haemonetics Corporation (HAE) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2026	10.2×	(47.39%)
FY2025	19.3×	(34.70%)
FY2024	29.6×	(41.37%)
FY2023	50.4×	21.52%
FY2022	41.5×	(45.74%)
FY2021	76.5×	91.08%
FY2020	40.0×	(62.68%)
FY2019	107×	317.75%
FY2018	25.7×	6.12%
FY2017	24.2×	(72.70%)

Period	Price to free cash flow	Change
Sep 2026	15.5×	33.19%
Jun 2026	11.6×	14.51%
Mar 2026	10.2×	(15.68%)
Dec 2025	12.0×	34.59%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 3,218×

Ten-year median 35.7×

Current reading's percentile 17

Company	Price to free cash flow
HAE Haemonetics Corporation	18.1×
BIO Bio-Rad Laboratories, Inc. compare	30.0×
BIO.B Bio-Rad Laboratories, Inc. compare	30.7×
BRKR Bruker Corporation compare	32.9×
LIVN LivaNova PLC compare	38.0×
ITGR Integer Holdings Corporation compare	53.3×
TXG 10x Genomics compare	63.3×
AXGN AxoGen, Inc. compare	134×
IRTC iRhythm Holdings, Inc. compare	584×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Haemonetics Corporation (HAE) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on HAE

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on HAE

Stockrow Weekly